PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34528900-0	2021	Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.	Metformin	0-9	tumor protein p53	Homo sapiens	61-64	
34528900-3	2021	Here we test if the presence of P53 could predict the activity of metformin as an adjuvant for cisplatin-based therapy in non-small cell lung cancer (NSCLC).	Metformin	66-75	tumor protein p53	Homo sapiens	32-35	
34528900-7	2021	Metformin sensitized A549 and HCC 827 cells (but not H1299 and H358 cells) to cisplatin in a P53-dependent manner, changing its subcellular localization to the mitochondria.	Metformin	0-9	tumor protein p53	Homo sapiens	93-96	
34528900-8	2021	Treatment with a sub-lethal dose of cisplatin increased Jarid1b expression, yet downregulated P53 levels, protecting A549Res cells from metformin-induced chemosensitization to cisplatin and favored a glycolytic phenotype.	Metformin	136-145	tumor protein p53	Homo sapiens	94-97	
34528900-10	2021	In conclusion, metformin could potentially be used as an adjuvant for cisplatin-based therapy in NSCLC cells if wild type P53 is present.	Metformin	15-24	tumor protein p53	Homo sapiens	122-125